Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439296 · ClinicalTrials.gov registry record · Phase 1
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
A Phase 1 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00439296 is a Phase 1 study that was terminated before completion, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 9 participants.
The verdict
NCT00439296, a Phase 1 study, was terminated before completion, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.
Interventions
- DRUG Doxorubicin
- DRUG Dexamethasone
- DRUG Cytarabine
- DRUG PEG-asparaginase
- DRUG ABT-751
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-05-22 |
| Est. Completion | 2009-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439296
The ClinicalTrials.gov registry entry for NCT00439296 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT00439296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439296 about?
NCT00439296 is a clinical study titled "ABT-751 With Chemotherapy for Relapsed Pediatric ALL". This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose...
What is the current status of trial NCT00439296?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-05-22. Estimated completion is 2009-09-23.
What interventions are being tested in trial NCT00439296?
The interventions under investigation include: Doxorubicin (DRUG), Dexamethasone (DRUG), Cytarabine (DRUG), PEG-asparaginase (DRUG), ABT-751 (DRUG).
Who is sponsoring clinical trial NCT00439296?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.